

February 13, 2019

TAKE/BSE/2018-19

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001

TAKE/NSE/2018-19

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Dear Sir/Madam,

Sub: Press Release

Ref: NSE Scrip Code: 523890 & BSE Scrip Code: TAKE

We are pleased to enclose a press release for your reference and record.

Kindly take note of the same.

Thanking you.

Yours sincerely,
For TAKE Solutions Limited


Avaneesh Singh
Company Secretary



Encl: As above.



TAKE Solutions announces acquisition of DataCeutics Inc to augment global Clinical Data Science Services

- Acquires DataCeutics in an INR 318 Crores deal
- Strong Quarter 3 results with revenue growth to INR 521.6 Crores

Consolidated Financial Highlights - Figures in INR million

Particulars	Q3 FY19	Q3 FY18	Change (%)
			Y-o-Y
Op. Revenue	5,216.4	4,080.2	27.8%
Op. EBITDA	882.3	798.1	10.4%
Margin	16.9%	19.6%	
Adj. EBITDA	1,034.4	798.1	29.5%
Margin	19.8%	19.6%	
Net Profit (PAT)	363.7	419.6	-13.3%
Margin	7.0%	10.3%	
Diluted EPS	2.44	3.13	

Chennai - India, February 13, 2019: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences, today announced will be acquiring Life Sciences services player, DataCeutics in North America. The company today declared its financial results for Q3FY19.

The acquisition as part of the 2021 growth strategy spearheads the growth of Clinical business in accordance with the global Clinical market which is expected to reach \$32.9 Bn by 2020 . TAKE is poised to gain from the strategic acquisition of DataCeutics, a specialty Clinical Functional Service Provider (FSP) providing quality SAS based statistical programming, clinical reporting and clinical data management. DataCeutics strengthens TAKE in its high-end Data Sciences capabilities that include Clinical Data Management, Biostatistics and Statistical programming, Medical Writing, Data Standards and conversions as well as depth of major pharma relationships in North America. TAKE plans to complement DataCeutics' capabilities with its own AI-driven clinical platform and near real-time data insights and analytics to deliver improved outcomes for clients across safety, quality, compliance, cycle time and cost. The company has core Clinical Functional Service Provider (FSP) experience and experienced resources in Oncology, Cardiology, Pulmonology, Infectious Disease and CNS.

TAKE reported a revenue growth of INR 5,216.4 Mn, registering a growth of 27.8% as against INR 4080.2 Mn in the corresponding quarter of FY18. Total income rose 28.1% to INR 5,243.3 Mn in Q3FY19 as compared to INR 4,093.9 Mn in Q3FY18.

Operating Revenue for YTD Q3 FY19 stood at INR 15,050.6 Mn registering a growth of 32.8% against corresponding period. Operating Earnings before Interest, Depreciation and Tax (EBIDTA) for YTD Q3FY19 stood at INR 2,868.6 Mn with a EBITDA margin 19.1%.

Key Highlights from this quarter:

- Revenue at **INR 5,216.4 Mn**; growth of **27.8% Y-o-Y**
- Stable order book growth



- Awarded 5-year renewal contract from top 5 global pharma company for Regulatory Submissions Services upwards of USD 15M
- Added 2 significant new clients to its clientele portfolio in Europe
- Augmented Senior Leadership team with the addition of Global Head of Clinical

Ram Yeleswarapu, President and CEO, TAKE Solutions said, *“We are delighted to begin 2019 on a high note with this key acquisition. DataCeutics strengthens our capabilities in Data Sciences and FSP / BPO services and widens our therapeutic expertise in Cardiology, Oncology, Pulmonology, CNS, Infectious diseases etc. The addition of these competencies translates to business expansion in North America, Europe and Asian markets.”*

He further added, *“Our quarter 3 results indicate a strong orderbook growth and an on target YoY growth. We are looking forward to bolstering the Clinical business further translating to a healthier pipeline in the coming quarters.”*

Benefits of the acquisitions

- Targets the largely untapped and continuously evolving Data Sciences field supporting R&D efforts of novel therapies across various indications
- Enhances therapeutic expertise in Cardiology, Oncology, Pulmonology, Mental health, Musculoskeletal diseases, CNS, infectious diseases
- Life Sciences expertise up by 10%
- Combined footprint will further cover US, Europe, Asia

About TAKE Solutions

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Our range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Our global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers.

With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with FY18 revenues touching INR 15,872 Mn, (USD 246 Mn).

For more details, please visit www.takesolutions.com

For media information:

Rajeswari Pradeep Kumar, TAKE Solutions, +91 44 66110700, rajeswari.p@takesolutions.com